For older sufferers with most cancers and kind 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is related to decrease all-cause mortality than dipeptidyl peptidase-4 inhibitor (DPP4i) use, in keeping with a examine printed on-line July 18 in JAMA Community Open.
Rotana M. Radwan, Ph.D., from the College of Florida in Gainesville, and colleagues examined whether or not GLP-1 RA use in contrast with sodium-glucose cotransporter-2 inhibitor (SGLT2i) and DPP4i use is related to improved survival in sufferers with most cancers and T2D in a retrospective cohort examine utilizing 2013 to 2020 Medicare information. Eligible sufferers have been aged 66 years or older and had T2D and one in all 9 cancers (thyroid, pancreatic, bladder, colorectal, lung, kidney, breast, endometrial, or prostate). Propensity rating matching was carried out to scale back confounding.
The GLP-1 RA versus SGLT2i cohort included 2,553 matched pairs, and the GLP-1 RA versus DPP4i cohort included 2,564 matched pairs. The researchers discovered no vital distinction in mortality danger between GLP-1 RA and SGLT2i customers. Nevertheless, considerably decrease mortality was seen in affiliation with GLP-1 RA versus DPP4i use (hazard ratio, 0.60). The E-value was 1.21 and a pair of.73 for GLP-1 RA versus SGLT2i use and for GLP-1 RA versus DPP4i use, respectively. No vital variations have been seen between GLP-1 RAs and SGLT2is in subgroup analyses; the survival profit remained constant throughout age, intercourse, non-Hispanic White race, and several other most cancers varieties (colorectal, lung, and breast) for GLP-1 RAs versus DPP4is.
“While causality cannot be inferred, our study adds novel evidence on the comparative effectiveness of GLP-1 RAs,” the authors write. “The observed survival differences may reflect drug class-specific systemic effects.”
A number of authors disclosed ties to the biopharmaceutical trade.
Extra info:
Rotana M. Radwan et al, GLP-1 RA Use and Survival Amongst Older Adults With Most cancers and Sort 2 Diabetes, JAMA Community Open (2025). DOI: 10.1001/jamanetworkopen.2025.21887
Quotation:
GLP-1 receptor agonist use linked to decrease mortality in seniors with most cancers, T2D (2025, July 24)
retrieved 24 July 2025
from https://medicalxpress.com/information/2025-07-glp-receptor-agonist-linked-mortality.html
This doc is topic to copyright. Other than any honest dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for info functions solely.
